BP-198
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


BP-198
Description :
BP-198 is an Mpro PROTAC degrader. BP-198 promotes the ubiquitination and degradation of Mpro. BP-198 has antiviral effects against SARS-CoV-2 (IC50: 11.8 μM) and has stronger activity against drug-resistant viruses. (Pink: target protein ligand (HY-176442) ; blue: E3 ligase ligand (HY-176441) ; black: linker (HY-W457968) ; E3 ligase-linker conjugate (HY-176443) ) [1].UNSPSC :
12352005Target :
PROTACs; SARS-CoV; Virus ProteaseRelated Pathways :
Anti-infection; PROTACApplications :
COVID-19-anti-virusField of Research :
InfectionSmiles :
C[C@@H](C(N[C@@H](C1CCCCC1)C(N2CCC[C@H]2C3=NC(C(C4=CC(OCCCN5N=NC(CSC(C)([C@H](NC(C(F)(F)F)=O)C(N6[C@H](C(N[C@H](C#N)C[C@@H]7CCNC7=O)=O)[C@]8([H])[C@](C8(C)C)([H])C6)=O)C)=C5)=CC=C4)=O)=CS3)=O)=O)NC.OC(C(F)(F)F)=OMolecular Formula :
C56H72F6N12O10S2Molecular Weight :
1251.37References & Citations :
[1]Pan B, et al. Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. Commun Med (Lond) . 2025 Apr 26;5 (1) :140.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
No Development Reported

